TowerJazz and Genoray Announce Successful Development of Industry Changing CMOS Image Sensor for Medical Diagnostic Devices
Replaces Existing Market Solution with 100um Pixel Size, Higher Resolution, Reduction in X-ray Radiation and Optimized Images for more Cost-effective Medical Equipment
Market for CMOS Imaging for
MIGDAL HAEMEK,
This new device is a CIS detector whereas the existing market uses a silicon TFT type sensor. The advantage of CIS compared to TFT is that CIS uses active pixels so it obtains the image with less noise and helps minimize X-ray radiation exposure which is currently the biggest issue in the industry. Furthermore, Genoray’s single detector supports both CT mode and Panorama mode while the existing products in the market only support one by one (CT supports only CT mode, Panorama supports Panorama mode only). This means that by providing multi-functions through one detector, Genoray can satisfy customers who need both modes with a less expensive price point; a competitive advantage of this product.
Genoray is targeting to replace the current market solution with this new, more efficient detector, providing a more cost-effective solution for medical equipment. The imaging device was manufactured using TowerJazz’s optimized pixel and stitch process which is able to maximize performance and offers a strong pixel structure towards radiographic exposure.
Stitching is a technology that enables the manufacture of products where the die size is greater than the area available with a single photo mask. With this technology, it is possible to produce dies up to full wafer size. TowerJazz has many years of production experience with stitching and owns the related patents. In addition, TowerJazz provides a 0.18um CIS PDK with outstanding modeling which helps to implement a very accurate read-out peripheral circuit in a limited timeframe.
As Genoray’s device can be applied in different types of medical
equipment, its expected production volume is sizable, reaching multiple
thousand wafer per year run rates. Genoray is engaged with numerous
local and global supply chains and mass production is expected to
successfully start in the near future. According to IHS, the market for
CMOS imaging for medical electronics is growing rapidly from
“We are pleased that Genoray has successfully developed its medical
imaging sensor with TowerJazz’s CIS process and is gearing up to release
it to the market. We fully believe that this product will generate great
response and demand as Genoray is known for its stable technical
solutions and strong business power locally and globally. We hope that
this success will bring more opportunities to work continually with
Genoray for further technological achievements,” said Dr.
“With great support from TowerJazz, finally a new CIS image sensor for
X-ray equipment was developed. TowerJazz’s industry leading CIS process
is well-known for superior performance. I have no doubt that the
collaboration between TowerJazz and Genoray will bring a successful
outcome for production in terms of quality and production size,” said In
Besides this CIS detector development, TowerJazz and Genoray are consistently working together and making investments to develop various other innovative applications.
About Genoray
With the mission of 'Providing Better Tools for Diagnosis,' Genoray, as an industry leader, strives continuously to improve its products and innovation of its diagnostic imaging systems. Founded in 2001, Genoray’s technical experts' will to manufacture the world’s best products is still at the heart of its business. With growing demand from numerous local and global customers, the company is increasing the supply of its valuable products through its technological and manufacturing expertise. Genoray will continue to strive to develop higher grade C-Arms, dental X-ray images as well as steadily improve its dental CT and industrial X-ray machines, among others. For more information, please visit: www.genoray.com.
About TowerJazz
Safe Harbor Regarding Forward-Looking Statements
This press release includes forward-looking statements, which are
subject to risks and uncertainties. Actual results may vary from those
projected or implied by such forward-looking statements. A complete
discussion of risks and uncertainties that may affect the accuracy of
forward-looking statements included in this press release or which may
otherwise affect TowerJazz’s business is included under the heading
"Risk Factors" in Tower’s most recent filings on Forms 20-F, F-3, F-4
and 6-K, as were filed with the
Source: TowerJazz
TowerJazz Company Contact in Asia:
Shoko Saimiya,
81-795-23-6609
saimiya@towerjazz.com
or
TowerJazz
Investor Relations Contact:
Noit Levi, +972-4-604-7066
noit.levi@towerjazz.com
or
Genoray
Company Contact:
In Jae Lee, +82-31-740-3955
ijlee@genoray.com